Negotiations between Taiwan’s Financial Supervisory Commission (FSC) and insurance companies regarding coverage for at-home chemotherapy have stalled. Stone Chung-liang, a key figure in the discussions, suggested a potential compromise involving discounted claim payouts could still lead to a mutually beneficial outcome. The core dispute centers on pricing and the scope of services included in at-home chemotherapy packages. Insurers expressed concerns over the cost-effectiveness and potential risks associated with providing such services outside of hospital settings. The FSC had been pushing for broader coverage to alleviate pressure on hospital beds and offer patients more convenient treatment options. While a complete agreement appears unlikely in the immediate future, Chung-liang remains optimistic that a revised proposal addressing insurer concerns could revive the initiative. The failure to reach an agreement impacts patients seeking alternatives to traditional hospital-based cancer treatment.